HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SENS-401

derivative of azasetron

Also Known As:

R-azasetron besylate

Networked: 2 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - SENS-401: 2
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - SENS-401: 2

Experts

1.	Broussy, Audrey: 2 articles (01/2019 - 10/2017)
2.	Dyhrfjeld-Johnsen, Jonas: 2 articles (01/2019 - 10/2017)
3.	Petremann, Mathieu: 2 articles (01/2019 - 10/2017)
4.	Romanet, Charlotte: 2 articles (01/2019 - 10/2017)
5.	Poli, Sonia: 1 article (01/2019)
6.	Van Ba, Christophe Tran: 1 article (01/2019)
7.	Tran Van Ba, Christophe: 1 article (10/2017)

Related Diseases

1.	Hearing Loss (Hearing Impairment) 10/01/2017 - "SENS-401 has previously been shown to improve acoustic trauma-induced hearing loss in vivo. " 01/01/2019 - "Improvements in hearing loss recovery make SENS-401 a promising clinical candidate for acoustic trauma-induced hearing loss, including when treatment is not initiated immediately." 01/01/2019 - "SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours." 10/01/2017 - "Auditory brainstem response and distortion product otoacoustic emission tests were performed in a rat model of cisplatin-induced hearing-loss (8 mg/kg, day 1) at baseline, and after 14 days of SENS-401 (6.6, 13.2, 26.4 mg/kg/d). " 10/01/2017 - "SENS-401, an oral clinical-stage drug, may reduce cisplatin-induced hearing loss and cochlear damage in an in vivo model. "
2.	Noise-Induced Hearing Loss (Acoustic Trauma) 10/01/2017 - "SENS-401 has previously been shown to improve acoustic trauma-induced hearing loss in vivo. " 01/01/2019 - "Improvements in hearing loss recovery make SENS-401 a promising clinical candidate for acoustic trauma-induced hearing loss, including when treatment is not initiated immediately." 01/01/2019 - "SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96 hours." 01/01/2019 - "The dose-response relationship of SENS-401 (6.6 mg/kg BID, 13.2 mg/kg BID, 26.4 mg/kg QD) and treatment time-window (13.2 mg/kg BID starting 24, 72, and 96 h posttrauma) versus placebo for 28 days were evaluated in a male rat model of severe acoustic trauma-induced hearing loss (120 dB SPL, 2 h) using auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) measures followed by cochlear outer hair cell (OHC) counting with myosin-VIIa immunolabeling. " 01/01/2019 - "SENS-401 (R-azasetron besylate) is effective against severe acoustic trauma-induced hearing loss. "
3.	Body Weight (Weight, Body) 10/01/2017 - "Body weight and survival were not significantly different between rats receiving placebo and those receiving 26.4 mg/kg SENS-401. "
4.	Ototoxicity 10/01/2017 - "Oral SENS-401 is a promising candidate for treating cisplatin-induced ototoxicity."

Related Drugs and Biologics

1.	SENS-401
2.	Cisplatin (Platino)
3.	Calcineurin
4.	Myosin VIIa

Related Therapies and Procedures

1.	Oral Administration